Episode 128

Published on:

4th Aug 2023

MIRA Pharmaceuticals, Inc. Erez Aminov, CEO

MIRA is developing a new

molecular synthetic THC analog called MIRA1a, designed for the treatment of

adult patients with anxiety and cognitive decline, typically associated with

early-stage dementia.


MIRA’s initial focus will

be a dual path: potentially winning in traditional pain and anxiety markets as

well as the marijuana analog markets with a potentially safe and effective option if approved

by the FDA.

Show artwork for The Wall Street Resource

About the Podcast

The Wall Street Resource
Your resource for microcap discovery and due diligence
As part of the investment process, we have conducted countless CEO and executive interviews, and found this to be an invaluable use of time. We provide The Wall Street Resource, not only to help you leverage your time, but for discovery and a starting point for due diligence.

About your host

Profile picture for Jeff Kone

Jeff Kone

Managing Member and portfolio manager of a micro-cap fund for over 15 years. Securities experience that encompasses almost all aspects of the industry (buy side, sell side, retail, institutional and investment banking). Degree from University of Southern California with a Bachelor of Science in Business, emphasis in Entrepreneurship.